Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation For Severe Congenital Anemias Including Sickle Cell Disease (SCD) and Beta-Thalassemia
Phase of Trial: Phase II
Latest Information Update: 02 Apr 2018
At a glance
- Drugs Alemtuzumab (Primary) ; Sirolimus (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 07 Feb 2018 Planned End Date changed from 31 Jan 2018 to 31 Jan 2019.
- 07 Feb 2018 Planned primary completion date changed from 31 Jan 2018 to 31 Jan 2019.
- 08 Jul 2017 Planned number of patients changed from 124 to 150.